DB2313 是一种有效的转录因子 PU.1 抑制剂，IC50 为 14 nM。DB2313 破坏了 PU.1 与靶基因启动子的相互作用。DB2313 可诱导急性髓细胞性白血病 (AML) 细胞Apoptosis" style="display: inline; color: #c13a36">凋亡 (Apoptosis)，并具有抗癌作用。

DB2313 is a potent transcription factor PU.1 inhibitor, IC50=14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects

DB2313 decreases PU.1 occupancy on E2f1, Junb, and Csf1r promoters in AML cells. DB2313 treatment leads to a profound decrease in the growth of PU.1 URE–/– acute myeloid leukemia (AML) cells (IC50 of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE–/– AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating[1].

DB2313 (17 mg/kg; i.p.; three times per week for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice.

2170606-74-1

C42H41FN8O2

708.83

Carboximidamide

DMSO:3 mg/mL (4.2 mM),ultrasonic and warming and heat to 70°C
Powder: -20°C for 3 years
In solvent: -80°C for 2 years